報價延遲最少15分鐘:2024/12/23 22:26 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
57.04 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.08/0.53
|
|
企業價值
2.87B
|
| 資產負債 |
|
每股賬面淨值
5.22
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
197.52M
|
|
每股收益
3.75
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:26 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |